Extracellular matrix remodeling in atrial fibrosis: Mechanisms and implications in atrial fibrillation

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 3, 2010, Pages 461-467

  Pellman, Jason ^a   Lyon, Robert C ^a   Sheikh, Farah ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Animal models; Atrial fibrillation; Atrial fibrosis; Collagen; Extracellular matrix; Mineralocorticoid receptor; Molecular mechanisms; Spironolactone; Ventricular fibrosis

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN; CALCIUM CHANNEL L TYPE; CANDESARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; EPLERENONE; FIBRILLIN 1; FIBROMODULIN; FUROSEMIDE; LOSARTAN; MINERALOCORTICOID RECEPTOR; PIOGLITAZONE; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

CALCIUM TRANSPORT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; EXTRACELLULAR MATRIX; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; INFLAMMATION; MITRAL VALVE REGURGITATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATRIAL FIBRILLATION; EXTRACELLULAR MATRIX; FIBROSIS; HEART ATRIA; HUMANS; SIGNAL TRANSDUCTION; SPIRONOLACTONE;

ANIMALIA;

EID: 77649275355     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.09.001     Document Type: Review

References (68)

1. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
2. Mazzini M.J., Monahan K.M. Pharmacotherapy for atrial arrhythmias: present and future. Heart Rhythm 2008, 5:S26-31.
3. Callans D.J. Apples and oranges: comparing antiarrhythmic drugs and catheter ablation for treatment of atrial fibrillation. Circulation 2008, 118:2488-2490.
4. Bajpai A., Savelieva I., Camm A.J. Treatment of atrial fibrillation. Br. Med. Bull. 2008, 88:75-94.
5. Kagitani S., Ueno H., Hirade S., Takahashi T., Takata M., Inoue H. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J. Hypertens. 2004, 22:1007-1015.
6. Brilla C.G., Matsubara L.S., Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol. 1993, 25:563-575.
7. Brilla C.G., Pick R., Tan L.B., Janicki J.S., Weber K.T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 1990, 67:1355-1364.
8. Yang S.S., Han W., Zhou H.Y., Dong G., Wang B.C., Huo H., et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin. Med. J. (Engl) 2008, 121:38-42.
9. Robert V., Heymes C., Silvestre J.S., Sabri A., Swynghedauw B., Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999, 33:981-986.
10. Johar S., Cave A.C., Narayanapanicker A., Grieve D.J., Shah A.M. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006, 20:1546-1548.
11. Thiedemann K.U., Ferrans V.J. Left atrial ultrastructure in mitral valvular disease. Am. J. Pathol. 1977, 89:575-604.
12. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997, 96:1180-1184.
13. Remes J., van Brakel T.J., Bolotin G., Garber C., de Jong M.M., van der Veen F.H., et al. Persistent atrial fibrillation in a goat model of chronic left atrial overload. J. Thorac. Cardiovasc. Surg. 2008, 136:1005-1011.
14. Verheule S., Sato T., Everett T.t., Engle S.K., Otten D., Rubart-von der Lohe M., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ. Res. 2004, 94:1458-1465.
15. Sanfilippo A.J., Abascal V.M., Sheehan M., Oertel L.B., Harrigan P., Hughes R.A., et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990, 82:792-797.
16. Verheule S., Wilson E., Everett T.t., Shanbhag S., Golden C., Olgin J. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 2003, 107:2615-2622.
17. Knackstedt C., Gramley F., Schimpf T., Mischke K., Zarse M., Plisiene J., et al. Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation. Cardiovasc. Pathol. 2008, 17:318-324.
18. Van Wagoner D.R. Electrophysiological remodeling in human atrial fibrillation. Pacing Clin. Electrophysiol. 2003, 26:1572-1575.
19. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995, 92:1954-1968.
20. Dhein S. Role of connexins in atrial fibrillation. Adv. Cardiol. 2006, 42:161-174.
21. Luo M.H., Li Y.S., Yang K.P. Fibrosis of collagen I and remodeling of connexin 43 in atrial myocardium of patients with atrial fibrillation. Cardiology 2007, 107:248-253.
22. Dhein S., Polontchouk L., Salameh A., Haefliger J.A. Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40. Biol. Cell 2002, 94:409-422.
23. Cha T.J., Ehrlich J.R., Zhang L., Shi Y.F., Tardif J.C., Leung T.K., et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 2004, 109:412-418.
24. Tsai C.T., Lai L.P., Hwang J.J., Lin J.L., Chiang F.T. Molecular genetics of atrial fibrillation. J. Am. Coll. Cardiol. 2008, 52:241-250.
25. Schotten U., de Haan S., Neuberger H.R., Eijsbouts S., Blaauw Y., Tieleman R., et al. Loss of atrial contractility is primary cause of atrial dilatation during first days of atrial fibrillation. Am. J. Physiol., Heart Circ. Physiol. 2004, 287:H2324-2331.
26. Li X., Zima A.V., Sheikh F., Blatter L.A., Chen J. Endothelin-1-induced arrhythmogenic Ca2+ signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate(IP3)-receptor type 2-deficient mice. Circ. Res. 2005, 96:1274-1281.
27. Eckstein J., Verheule S., de Groot N.M., Allessie M., Schotten U. Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. Prog. Biophys. Mol. Biol. 2008, 97:435-451.
28. Young M.J. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 2008, 17:174-180.
29. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 1992, 120:893-901.
30. Sun Y., Ramires F.J., Weber K.T. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc. Res. 1997, 35:138-147.
31. Schmidt B.M., Schmieder R.E. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am. J. Hypertens. 2003, 16:80-86.
32. Silvestre J.S., Robert V., Heymes C., Aupetit-Faisant B., Mouas C., Moalic J.M., et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 1998, 273:4883-4891.
33. Rocha R., Stier C.T., Kifor I., Ochoa-Maya M.R., Rennke H.G., Williams G.H., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871-3878.
34. Hood W.G., Hill R., Pittman J.A., Farmer T.A. Studies on the metabolic effects of spironolactone in man. Ann. N.Y. Acad. Sci. 1960, 88:864-880.
35. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999, 341:709-717.
36. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
37. Shehab A., Elnour A.A., Struthers A.D. A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. Cardiovasc. J. Afr. 2008, 19:292-296.
38. Milliez P., Deangelis N., Rucker-Martin C., Leenhardt A., Vicaut E., Robidel E., et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur. Heart J. 2005, 26:2193-2199.
39. Bunda S., Wang Y., Mitts T.F., Liu P., Arab S., Arabkhari M., et al. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 2009, 284:16633-16647.
40. Nishioka T., Suzuki M., Onishi K., Takakura N., Inada H., Yoshida T., et al. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J. Cardiovasc. Pharmacol. 2007, 49:261-268.
41. Barnes B.J., Howard P.A. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure. Ann. Pharmacother. 2005, 39:68-76.
42. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348:1309-1321.
43. Akashiba A., Ono H., Ono Y., Ishimitsu T., Matsuoka H. Valsartan improves l-NAME-exacerbated cardiac fibrosis with TGF-beta inhibition and apoptosis induction in spontaneously hypertensive rats. J. Cardiol. 2008, 52:239-246.
44. Kumagai K., Nakashima H., Urata H., Gondo N., Arakawa K., Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 2003, 41:2197-2204.
45. Disertori M., Latini R., Barlera S., Franzosi M.G., Staszewsky L., Maggioni A.P., et al. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 2009, 360:1606-1617.
46. Zhao W., Zhao T., Chen Y., Ahokas R.A., Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol. Cell. Biochem. 2008, 317:43-50.
47. Shimano M., Tsuji Y., Inden Y., Kitamura K., Uchikawa T., Harata S., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008, 5:451-459.
48. Xiao H.D., Fuchs S., Campbell D.J., Lewis W., Dudley S.C., Kasi V.S., et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am. J. Pathol. 2004, 165:1019-1032.
49. Nakajima H., Nakajima H.O., Salcher O., Dittie A.S., Dembowsky K., Jing S., et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ. Res. 2000, 86:571-579.
50. Paradis P., Dali-Youcef N., Paradis F.W., Thibault G., Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:931-936.
51. Bauer P., Regitz-Zagrosek V., Kallisch H., Linz W., Schoelkens B., Hildebrandt A.G., et al. Myocardial angiotensin receptor type 1 gene expression in a rat model of cardiac volume overload. Basic Res. Cardiol. 1997, 92:139-146.
52. Burstein B., Libby E., Calderone A., Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 2008, 117:1630-1641.
53. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52:415-472.
54. Lymperopoulos A., Rengo G., Zincarelli C., Kim J., Soltys S., Koch W.J. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5825-5830.
55. Kassiri Z., Khokha R. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb. Haemost. 2005, 93:212-219.
56. Herpel E., Pritsch M., Koch A., Dengler T.J., Schirmacher P., Schnabel P.A. Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy. Histopathology 2006, 48:736-747.
57. Cardin S., Libby E., Pelletier P., Le Bouter S., Shiroshita-Takeshita A., Le Meur N., et al. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ. Res. 2007, 100:425-433.
58. Bouzeghrane F., Reinhardt D.P., Reudelhuber T.L., Thibault G. Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis. Am. J. Physiol., Heart Circ. Physiol. 2005, 289:H982-991.
59. Lin C.S., Lai L.P., Lin J.L., Sun Y.L., Hsu C.W., Chen C.L., et al. Increased expression of extracellular matrix proteins in rapid atrial pacing-induced atrial fibrillation. Heart Rhythm 2007, 4:938-949.
60. Ramirez F., Rifkin D.B. Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. Curr. Opin. Cell Biol. 2009.
61. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 2007, 87:1285-1342.
62. Mukherjee R., Herron A.R., Lowry A.S., Stroud R.E., Stroud M.R., Wharton J.M., et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am. J. Cardiol. 2006, 97:532-537.
63. Moe G.W., Laurent G., Doumanovskaia L., Konig A., Hu X., Dorian P. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure. J. Card. Fail. 2008, 14:768-776.
64. Baudino T.A., McFadden A., Fix C., Hastings J., Price R., Borg T.K. Cell patterning: interaction of cardiac myocytes and fibroblasts in three-dimensional culture. Microsc. Microanal. 2008, 14:117-125.
65. Hirose M., Takeishi Y., Niizeki T., Shimojo H., Nakada T., Kubota I., et al. Diacylglycerol kinase zeta inhibits G(alpha)q-induced atrial remodeling in transgenic mice. Heart Rhythm 2009, 6:78-84.
66. Zaman A.K., French C.J., Schneider D.J., Sobel B.E. A profibrotic effect of plasminogen activator inhibitor type-1 (PAI-1) in the heart. Exp. Biol. Med. (Maywood) 2009, 234:246-254.
67. Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 2009, 104:170-178. 6p following 8.
68. Recchia A.G., Filice E., Pellegrino D., Dobrina A., Cerra M.C., Maggiolini M. Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes. J. Mol. Cell. Cardiol. 2009, 46:352-359.